Neutralizing Power of Serum Antibodies - 2
Study of the Neutralizing Power of Serum Antibodies - 2 (PNAS-2)
Centre Hospitalier Régional d'Orléans
30 participants
Aug 22, 2025
INTERVENTIONAL
Conditions
Summary
Severe forms of COVID-19 and Monkeypox affect immunocompromised and comorbid individuals. Vaccination and monoclonal antibody therapies induce neutralizing antibodies. This neutralizing power is recognized as a correlate of protection against a new infection. This study aims to describe the neutralizing power of serum and nasal antibodies over time, in relation to SARS-CoV-2 and MPXV vaccines or treatments received.
Eligibility
Inclusion Criteria3
- Adults (≥18 years)
- Patients receiving or scheduled to receive anti-SARS-CoV-2 and/or anti-MPXV vaccines or monoclonal antibodies
- Patients have provided written informed consent
Exclusion Criteria5
- Persons under guardianship or curatorship
- Persons under legal protection,
- Persons persons deprived of liberty
- Persons not affiliated to a social security scheme
- Pregnant or breastfeeding women
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Venous blood collection (2 tubes of 6 mL) and optional nasal swab at each visit. Aliquots analyzed for neutralizing activity against SARS-CoV-2 and MPXV using validated assays at Institut Pasteur
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07085611